Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the ...
Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...
Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment
We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to ...
Katie Price shares Harvey health update and reveals sweet way she's made him feel at home
Mum-of-five Katie Price says son Harvey, 22, needs a little support with his walking and after cane training, his very own ...
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and ...
Embracing neurodivergence
For these reasons, and others, Australian sociologist Judy Singer, who coined the phrase neurodiversity, wanted the narrative ...
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
Soleno Therapeutics shows promise with DCCR for reducing hyperphagia in PWS patients. Learn more about why SLNO stock is ...
Soleno Therapeutics Jumps After FDA Says No Advisory Panel Meeting Needed for Prader-Willi Syndrome Drug
On Tuesday, the biopharmaceutical company said the U.S. Food and Drug Administration found no apparent need for an advisory committee meeting at this time for Soleno's application for DCCR, or ...
Soleno Therapeutics Says FDA Determines No Need For Advisory Committee Meeting For DCCR NDA
Providing a regulatory update from the U.S. Food and Drug Administration (FDA) on Tuesday, biopharmaceutical company Soleno ...
Soleno stock rises as NDA for lead asset doesn’t need FDA advisory meeting
Soleno Therapeutics (SLNO) shares rose 15% in premarket trade after FDA announced no advisory committee meeting needed for ...
TMCnet13d
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
The FDA Review Division has determined that there does not appear to be a need for an advisory committee meeting at this time for the New Drug Application (NDA) for DCCR (diazoxide choline) ...